Thomas R. W. Tipton

Learn More
Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs), ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has enhanced capacity for complement-dependent cytotoxicity, whereas obinutuzumab, a type II mAb, lacks the ability to redistribute into lipid rafts and is glycoengineered for augmented antibody-dependent(More)
FcγRs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through a variety of receptors, isoforms, and cellular expression patterns, they are able to fine-tune and direct appropriate responses. Furthermore, they are key determinants of mAb immunotherapy, with mAb(More)
Current treatment strategies for chronic lymphocytic leukemia (CLL) involve a combination of conventional chemotherapeutics, monoclonal antibodies, and targeted signaling inhibitors. However, CLL remains largely incurable, with drug resistance and treatment relapse a common occurrence, leading to the search for novel treatments. Mechanistic target of(More)
The serum bactericidal assay is the correlate of protection for meningococcal disease but the use and comparison of functional immunological assays for the assessment of meningococcal vaccines is complicated by the sourcing of human complement. This is due to high levels of immunity in the population acquired through natural meningococcal carriage and means(More)
To support the licensure of a new and safer vaccine to protect people against smallpox, a monkeypox model of infection in cynomolgus macaques, which simulates smallpox in humans, was used to evaluate two vaccines, Acam2000 and Imvamune, for protection against disease. Animals vaccinated with a single immunization of Imvamune were not protected completely(More)
Monoclonal antibodies (mAbs), such as the anti-CD20 mAb rituximab, have transformed the treatment of malignant disease and are now a firstline treatment ofmany hematologic conditions. Although inmany cases their precisemechanismof action isnot fully elucidated,where target cell deletion is critical to effective treatment, Fcg receptors (FcgRs) are now(More)
Beers and Mark S. Cragg Ingrid Teige, Bjorn Frendéus, Martin J. Glennie, Stephen A. Roghanian, Robert J. Oldham, Kerry L. Cox, Sean H. Lim, H. Kim, Elizabeth A. Potter, C. Ian Mockridge, Ali Dunscombe, H. T. Claude Chan, Christine A. Penfold, Jinny Alexander Earley, Lekh N. Dahal, Chen Lu, Melanie French, Khiyam Hussain, Andrew T. Vaughan, Lang Dou, Thomas(More)
Work with highly pathogenic material mandates the use of biological containment facilities, involving microbiological safety cabinets and specialist laboratory engineering structures typified by containment level 3 (CL3) and CL4 laboratories. Consequences of working in high containment are the practical difficulties associated with containing specialist(More)
  • 1